MassBio presents Cross-Border Biotech Collaborations: CFIUS & Other Risks

For early-stage research companies seeking equity capital or pursuing strategic alliances with foreign partners or investors, there are considerable risks to consider when conducting these transactions, whether on US soil or in foreign lands. Nonetheless, despite cumbersome impediments, more US biotech and medical device companies are pursuing these alliances or investments, believing that the risks are outweighed by the benefits.

The panel was moderated by John Hession, partner at Barnes-Brown & Pendleton, and included the following speakers/topics:

• Carl Valenstein, partner at Morgan Lewis: “CFIUS, Transactions with Chinese and Other Investors”
• Katherine Anderson, head of Healthcare Corporate Finance and East/Central Life Science, Silicon Valley Bank:“Investment Outlook 2018, BioPharma, Silicon Valley Bank”
• Larry Albert, co-founder and CEO, Cam Med: “Tales from the Trenches”